October 1, 2023

Dundee, Scotland, October 1, 2023 – Tay Therapeutics (“Tay”) today announced it has been awarded a £0.35 million grant from Innovate UK, supporting the development of its pioneering Readthrough compounds through in vitro and in vivo proof-of-concept studies. The grant funding will accelerate preclinical research aimed at transforming treatments for genetic diseases caused by premature stop codons.

Andrew Woodland, CEO and Co-founder of Tay Therapeutics, commented: “Many diseases are driven by premature stop codons. This grant will allow us to explore the ability of our Readthrough drugs to overcome such premature stop codons, restoring normal protein levels and cellular function”. 

This strategic grant from Innovate UK enhances Tay’s ability to advance its Readthrough platform, positioning the company for future partnerships, licensing opportunities, and clinical development milestones. By demonstrating proof of concept, Tay Therapeutics aims to attract further investment and expand its therapeutic pipeline in high-value markets.